Detection of specific human papillomavirus types in paraffin‐embedded sections of cervical carcinomas

Bryan, Janine T.; Taddeo, Frank J.; Skulsky, Dee Marie; Jansen, Kathrin U.; Frain, Barbara McGahey; Qadadri, Brahim; Brown, Darron R.

doi:10.1002/jmv.20512

Cited by 27 publications

(13 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Each thin-section and swab specimen was evaluated with three different primer-pair sets per HPV type, which amplified a portion of three separate open reading frames. 13 Less than 5% of the PCR-positive biopsy specimens from external genital lesions (11 of 268 positive specimens) were positive for only 1 of 3 genes, and less than 4% of all specimens from external genital lesions (151 of 4886) could not be amplified to at least 1 of 14 HPV types tested.…”

Section: Methodsmentioning

confidence: 88%

Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males

et al. 2011

View full text Add to dashboard Cite

BACKGROUND Infection with human papillomavirus (HPV) and diseases caused by HPV are common in boys and men. We report on the safety of a quadrivalent vaccine (active against HPV types 6, 11, 16, and 18) and on its efficacy in preventing the development of external genital lesions and anogenital HPV infection in boys and men. METHODS We enrolled 4065 healthy boys and men 16 to 26 years of age, from 18 countries in a randomized, placebo-controlled, double-blind trial. The primary efficacy objective was to show that the quadrivalent HPV vaccine reduced the incidence of external genital lesions related to HPV-6, 11, 16, or 18. Efficacy analyses were conducted in a per-protocol population, in which subjects received all three vaccinations and were negative for relevant HPV types at enrollment, and in an intention-to-treat population, in which subjects received vaccine or placebo, regardless of baseline HPV status. RESULTS In the intention-to-treat population, 36 external genital lesions were seen in the vaccine group as compared with 89 in the placebo group, for an observed efficacy of 60.2% (95% confidence interval [CI], 40.8 to 73.8); the efficacy was 65.5% (95% CI, 45.8 to 78.6) for lesions related to HPV-6, 11, 16, or 18. In the per-protocol population, efficacy against lesions related to HPV-6, 11, 16, or 18 was 90.4% (95% CI, 69.2 to 98.1). Efficacy with respect to persistent infection with HPV-6, 11, 16, or 18 and detection of related DNA at any time was 47.8% (95% CI, 36.0 to 57.6) and 27.1% (95% CI, 16.6 to 36.3), respectively, in the intention-to-treat population and 85.6% (97.5% CI, 73.4 to 92.9) and 44.7% (95% CI, 31.5 to 55.6) in the per-protocol population. Injection-site pain was significantly more frequent among subjects receiving quadrivalent HPV vaccine than among those receiving placebo (57% vs. 51%, P<0.001). CONCLUSIONS Quadrivalent HPV vaccine prevents infection with HPV-6, 11, 16, and 18 and the development of related external genital lesions in males 16 to 26 years of age. (Funded by Merck and others; ClinicalTrials.gov number, NCT00090285.)

show abstract

Section: Methodsmentioning

confidence: 88%

Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Globally, 83% of the cases of this cancer occur in developing areas, including sub-saharan Africa, Melanesia, latin America and the Caribbean, south-Central Asia and southeast Asia (14). While the causal relationship between HPV infection and squamous cell carcinoma of the genital tract is well established (15), the role of HPV in the development of the malignancy has yet to be elucidated. However, mounting evidence shows the involvement of HPV types in the process of oncogenesis.…”

Section: Discussionmentioning

confidence: 99%

Human papillomavirus infection induces NF-κB activation in cervical cancer: A comparison with penile cancer

Senba

Buziba

Mori³

et al. 2010

Oncology Letters

View full text Add to dashboard Cite

Abstract. This study aimed to determine the relationship between human papillomavirus (HPV) and nuclear factor-κB (NF-κB) in cervical cancer using 62 tissues of cervical cancer, and to compare the findings to penile cancer. HPV-DNA integration is a crucial factor for malignant transformation in cervical cancer and can be identified using in situ hybridization. Of the 62 cases, HPV infection was detected in 28 (45.2%). This frequency was lower than in penile cancer (68.2%) as shown by our previous study. The earliest age of onset of cervical and penile cancer was 18 and 35, respectively, whereas the mean age of the initial diagnosis of cervical and penile cancer was 50.1 and 59.6, respectively. The discrepancies of HPV prevalence, earliest ages of onset and mean ages between cervical and penile cancer patients may result from the gender-based synergistic action of HPV associated with multiple epidemiological co-factors. Of the 28 HPV-infected cases, NF-κB expression was observed in the nucleus in 18 (64.3%), in the cytoplasm in 19 (67.9%) and in the nucleus and/or cytoplasm in 27 cases (96.4%). The overexpression of NF-κB in cervical cancer cases suggests that NF-κB activation is a key modulator in driving chronic inflammation to cancer.

show abstract

“…(7) reported that FISH sensitivity to predict progression of cytologically low-grade or normal Pap-smears to invasive carcinoma was 100% with specificity of 70%. Meanwhile, FISH analysis could also predict the progression of uterine cervical dysplasia to invasive cancer with a higher accuracy (8–10). In the cytogenetic laboratories, interphase FISH image analysis is commonly used to detect or identify the deletion/duplication and specific translocation of small parts of genes.…”

Section: Introductionmentioning

confidence: 99%

Automated Analysis of Fluorescent in situ Hybridization (FISH) Labeled Genetic Biomarkers in Assisting Cervical Cancer Diagnosis

Wang

Zhang

et al. 2010

Technol Cancer Res Treat

View full text Add to dashboard Cite

The numerical and/or structural deviation of some chromosomes (i.e., monosomy and polysomy of chromosomes 3 and X) are routinely used as positive genetic biomarkers to diagnose cervical cancer and predict the disease progression. Among the available diagnostic methods to analyze the aneusomy of chromosomes 3 and X, fluorescence in situ hybridization (FISH) technology has demonstrated significant advantages in assisting clinicians to more accurately detect and diagnose cervical carcinoma at an early stage, in particular for the women at a high risk for progression of low-grade and high-grade squamous intra-epithelium lesions (LSIL and HSIL). In order to increase the diagnostic accuracy, consistency, and efficiency from that of manual FISH analysis, this study aims to develop and test an automated FISH analysis method that includes a two-stage scheme. In the first stage, an interactive multiple-threshold algorithm is utilized to segment potential interphase nuclei candidates distributed in different intensity levels and a rule-based classifier is implemented to identify analyzable interphase cells. In the second stage, FISH labeled biomarker spots of chromosomes 3 and X are segmented by a top-hat transform. The independent FISH spots are then detected by a knowledge-based classifier, which enables recognition of the splitting and stringy FISH signals. Finally, the ratio of abnormal interphase cells with numerical changes of chromosomes 3 and X is calculated to detect positive cases. The experimental results of four test cases showed high agreement of FISH analysis results between the automated scheme and the cytogeneticist’s analysis including 92.7% to 98.7% agreement in cell segmentation and 4.4% to 11.0% difference in cell classification. This preliminary study demonstrates that the feasibility of potentially applying the automatic FISH analysis method to expedite the screening and detecting cervical cancer at an early stage.

show abstract

Detection of specific human papillomavirus types in paraffin‐embedded sections of cervical carcinomas

Cited by 27 publications

References 15 publications

Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males

Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males

Human papillomavirus infection induces NF-κB activation in cervical cancer: A comparison with penile cancer

Automated Analysis of Fluorescent in situ Hybridization (FISH) Labeled Genetic Biomarkers in Assisting Cervical Cancer Diagnosis

Contact Info

Product

Resources

About